Compare HRZN & MOBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRZN | MOBI |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 366.1M |
| IPO Year | N/A | 2026 |
| Metric | HRZN | MOBI |
|---|---|---|
| Price | $4.67 | $11.89 |
| Analyst Decision | Hold | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 636.6K | 108.7K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 33.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $22.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $10.79 |
| 52 Week High | $8.46 | $15.19 |
| Indicator | HRZN | MOBI |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 41.38 |
| Support Level | $4.56 | $10.79 |
| Resistance Level | $4.74 | $13.88 |
| Average True Range (ATR) | 0.11 | 1.07 |
| MACD | 0.00 | -0.14 |
| Stochastic Oscillator | 48.44 | 27.50 |
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.